Genetic Technologies Limited
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinicall… Read more
Genetic Technologies Limited (GNTLF) - Total Assets
Latest total assets as of December 2024: $1.75 Million USD
Based on the latest financial reports, Genetic Technologies Limited (GNTLF) holds total assets worth $1.75 Million USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genetic Technologies Limited - Total Assets Trend (2000–2024)
This chart illustrates how Genetic Technologies Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Genetic Technologies Limited - Asset Composition Analysis
Current Asset Composition (June 2024)
Genetic Technologies Limited's total assets of $1.75 Million consist of 59.7% current assets and 40.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 16.5% |
| Accounts Receivable | $2.13 Million | 34.4% |
| Inventory | $206.47K | 3.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $360.06K | 5.8% |
| Goodwill | $1.78 Million | 28.9% |
Asset Composition Trend (2000–2024)
This chart illustrates how Genetic Technologies Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genetic Technologies Limited's current assets represent 59.7% of total assets in 2024, a decrease from 61.1% in 2000.
- Cash Position: Cash and equivalents constituted 16.5% of total assets in 2024, up from 13.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 34.4% of total assets.
Genetic Technologies Limited Competitors by Total Assets
Key competitors of Genetic Technologies Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Genetic Technologies Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Genetic Technologies Limited generates 1.56x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Genetic Technologies Limited is currently not profitable relative to its asset base.
Genetic Technologies Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.45 | 1.67 | 2.95 |
| Quick Ratio | 0.45 | 1.55 | 2.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.17 Million | $ 2.29 Million | $ 2.63 Million |
Genetic Technologies Limited - Advanced Valuation Insights
This section examines the relationship between Genetic Technologies Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 126.41 |
| Latest Market Cap to Assets Ratio | 0.94 |
| Asset Growth Rate (YoY) | -58.4% |
| Total Assets | $6.19 Million |
| Market Capitalization | $5.84 Million USD |
Valuation Analysis
Near Book Valuation: The market values Genetic Technologies Limited's assets close to their book value ( 0.94x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Genetic Technologies Limited's assets decreased by 58.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genetic Technologies Limited (2000–2024)
The table below shows the annual total assets of Genetic Technologies Limited from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | $6.19 Million | -58.36% |
| 2023-06-30 | $14.86 Million | -28.58% |
| 2022-06-30 | $20.80 Million | -9.45% |
| 2021-06-30 | $22.97 Million | +46.94% |
| 2020-06-30 | $15.63 Million | +378.80% |
| 2019-06-30 | $3.27 Million | -47.05% |
| 2018-06-30 | $6.17 Million | -49.08% |
| 2017-06-30 | $12.11 Million | -8.89% |
| 2016-06-30 | $13.29 Million | -35.86% |
| 2015-06-30 | $20.72 Million | +207.91% |
| 2014-06-30 | $6.73 Million | -19.12% |
| 2013-06-30 | $8.32 Million | -49.40% |
| 2012-06-30 | $16.44 Million | +84.28% |
| 2011-06-30 | $8.92 Million | +7.76% |
| 2010-06-30 | $8.28 Million | -62.83% |
| 2009-06-30 | $22.28 Million | -7.75% |
| 2008-06-30 | $24.15 Million | +15.25% |
| 2007-06-30 | $20.95 Million | -6.64% |
| 2006-06-30 | $22.44 Million | -23.31% |
| 2005-06-30 | $29.26 Million | +30.71% |
| 2004-06-30 | $22.39 Million | -25.97% |
| 2003-06-30 | $30.25 Million | -8.35% |
| 2002-06-30 | $33.00 Million | -16.84% |
| 2001-06-30 | $39.69 Million | +348.58% |
| 2000-06-30 | $8.85 Million | -- |